Rifamycin SV MMX® is a drug based on MMX® technology and Rifamycin SV. Rifamycin SV is a broad spectrum, semi-synthetic, orally non-absorbable antibiotic which can be used for the treatment of bacterial infections of the colon. Such infections are often diagnosed in conjunction with Inflammatory Bowel Diseases. The application of MMX® technology to Rifamycin SV allows the antibiotic to be delivered directly into the colon, avoiding unwanted effects on the bacterial flora living in the upper portions of the gastro-intestinal tract. The specific dissolution profile of Rifamycin SV MMX® tablets is thought to increase the colonic disposition of the antibiotic so that an optimized intestinal concentration is achieved thus reducing its early inactivation by metabolic reactions or dilution and thus abating its systemic absorption in the small intestine.

The phasae III trials starting in Q2 2010.

It is intended that Rifamycin SV MMX® will initially be indicated for the treatment of patients with travellers’ diarrhoea. A daily dosis of 800 mg, usually consisting of four tablets at 200 mg a day, is recommended.

Cosmo’s patent expires in the year 2025.



Back to top